Journal
DRUG RESISTANCE UPDATES
Volume 12, Issue 6, Pages 148-152Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2009.09.001
Keywords
ATP7B; Cisplatin; Chemoresistance; Drug transport; Kinases; MK-0457; Ovarian cancer; siRNA; Tumor stroma; BRCA1
Categories
Funding
- NIH/NICHD [HD050128, CA109298, CA110793]
- Ovarian Cancer Research Fund, Inc.
- Zarrow Foundation
- Marcus Foundation
- Anderson Cancer Center SPORE in Ovarian Cancer [P50 CA083639]
- EIF Foundation
- Betty Ann Asche Murray Distinguished Professorship
Ask authors/readers for more resources
Platinum-based drugs continue to be the mainstay of therapy for ovarian cancer. Along with adverse effects, chemoresistance (intrinsic or acquired) has become a major limitation in the management of recurrent disease. Even though much is known about the effects of platinum drugs on cancer cells, the mechanisms underlying resistance are poorly understood. In this review, we summarize the current data on chemoresistance and discuss novel strategies to reverse resistance to platinum-based drugs. The most important targets highlighted here include Aurora kinases, PARP, ATP7B, and ERCC1. Furthermore, we discuss the implications of these novel approaches for ovarian cancer treatment. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
